摘要
缺血性卒中(脑梗死)是老年人致残、致死的主要原因。脑梗死的广泛损伤由缺血再灌注引起,并伴随炎症、血脑屏障(BBB)损伤、神经细胞死亡和广泛的组织损伤。阿替普酶(rt-PA)是FDA批准的唯一用于静脉溶栓的药物,因其溶栓的治疗时间窗短、血管再通率低、出血转化风险高等缺点限制了其应用范围。神经干细胞(NSCs)在脑内固有存在,并在神经血管损伤后发生增殖、分化和迁移,表现出广泛的潜在治疗作用。NSCs移植治疗具有抗炎、抗细胞凋亡、促血管生成和神经发生等作用,可改善rt-PA溶栓治疗相关的一些副作用,是一种非常有潜力的治疗方法。
Ischemic stroke (cerebral infarction) is the main cause of disability and death in the elderly. Extensive injury caused by cerebral infarction results from ischemia-reperfusion, which combined with inflammation, blood-brain barrier (BBB) damage, nerve cell death and extensive tissue injury. Alteplase (rt-PA) is the only FDA-approved drugs for intravenous thrombolysis, but short treatment time window, low revascularization rate and high risk of hemorrhagic transformation limit its application. Neural stem cells (NSCs) are present in the brain and can proliferate, differentiate and migrate to the lesions after neurovascular injury, exhibiting a wide range of potential therapeutic effects. NSCs transplantation has the functions of anti-inflammatory, anti-apoptotic, pro-angiogenic and pro-neurogenesis, and can improve some side effects of rt-PA thrombolytic therapy, which is a very promising treatment method.
作者
王凌飞
WANG Lingfei(Department of Acupuncture and Moxibustion,First Teaching Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China)
出处
《沈阳医学院学报》
2019年第5期469-474,共6页
Journal of Shenyang Medical College
关键词
卒中
神经干细胞
移植
组织纤溶酶原激活剂
stroke
neural stem cells
transplantation
tissue plasminogen activator
